Tycel Jovelle Phillips, MD, University of Michigan

Dr. Phillips on the Current Role of Ibrutinib in MCL

February 3rd 2022

Tycel Jovelle Phillips, MD, discusses the current role of ibrutinib in mantle cell lymphoma.

Dr. Phillips on Considering Age During Treatment Selection With BTK Inhibitors in MCL

January 10th 2022

Tycel Jovelle Phillips, MD, discusses the importance of considering age during treatment selection for BTK inhibitors in mantle cell lymphoma.

Emerging Agents for R/R MZL

December 21st 2021

Drs. Alexey Danilov and Tycel Jovelle Phillips share insight on emerging agents and future directions for the management of marginal zone lymphoma.

Selecting the Appropriate Treatment in R/R MZL

December 21st 2021

Alexey Danilov, MD, and Tycel Jovelle Phillips, MD, discuss strategies for selecting the appropriate treatment for patients with relapsed/refractory marginal zone lymphoma.

CHRONOS-3 in MZL: Results and Clinical Implications

December 13th 2021

Tycel Jovelle Phillips, MD, discusses recent updates from the CHRONOS-3 trial of copanlisib in R/R MZL and clinical implications of the results of this study.

Treatment Options for MZL: Second Line and Beyond

December 13th 2021

Experts in hematology/oncology discuss second-line and beyond treatment options for patients with MZL and comment on copanlisib monotherapy for the management of R/R MZL as seen in the phase 2 CHRONOS-1 study.

Overview of Marginal Zone Lymphoma and Frontline Treatment

December 6th 2021

Tycel Jovelle Phillips, MD, and Alexey Danilov, MD, share insights on common signs and symptoms of marginal zone lymphoma and approaching initial therapy.

Novel Agents and Ongoing Trials in R/R Follicular Lymphoma

December 6th 2021

Dr Tycel Jovelle Phillips reviews key ongoing trials in relapsed/refractory follicular lymphoma.

Role of Tazemetostat and Selecting Appropriate Therapies in R/R FL

November 29th 2021

Expert hematologist-oncologists examine the use of tazemetostat based on a phase 2 trial for relapsed/refractory follicular lymphoma and consider clinical implications.

CHRONOS-1 and CHRONOS-3 Trials in R/R FL and Clinical Implications

November 29th 2021

Dr Alexey Danilov reviews the 2-year follow-up of the phase 2 CHRONOS-1 study evaluating the use of copanlisib monotherapy in relapsed/refractory follicular lymphoma.

Treatment Options for Follicular Lymphoma: Second Line and Beyond

November 22nd 2021

Tycel Jovelle Phillps, MD, shares second-line treatment approaches for the management of follicular lymphoma and examines the use of PI3K inhibitors.

Overview of Follicular Lymphoma and Frontline Treatment

November 22nd 2021

Alexey Danilov, MD, and Tycel Jovelle Phillips, MD, provide insight on common signs and symptoms of follicular lymphoma (FL) and factors to consider when selecting first-line therapy.

Dr. Phillips on the Future of CAR T-Cell Therapy in MCL

August 2nd 2021

Tycel Jovelle Phillips, MD, discusses the future of CAR T-cell therapy in mantle cell lymphoma patients.

ADCs for Relapsed/Refractory DLBCL: Next Steps

July 20th 2021

Tycel Jovelle Phillips, MD, reviews current therapy options for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and how he selects among these options and highlights some potential new therapies.

Relapsed/Refractory DLBCL: Sequencing Therapy

July 20th 2021

Tycel Jovelle Phillips, MD, of the University of Michigan, comments on his preferences for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and shares his expectations for sequencing with newer, novel approaches emerging in the field.

Safety of Loncastuximab Tesirine for Relapsed/Refractory DLBCL

July 20th 2021

Recommendations for mitigating and managing common treatment-related adverse events associated with loncastuximab tesirine based on safety data from LOTIS-2 and variables that may impact patient candidacy.

Loncastuximab Tesirine for Relapsed/Refractory DLBCL

July 13th 2021

Potential implications for treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with loncastuximab tesirine, an antibody-drug conjugate, based on early results demonstrated by the LOTIS-2 study.

Treatment Advances in Relapsed/Refractory DLBCL

July 13th 2021

A historical overview of treatment advances for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and the rationale for treating appropriate patients with an approved antibody-drug conjugate therapy.

Rapid Readouts: Results from the Phase 3 CHRONOS-3 Trial for Relapsed iNHL

May 7th 2021

Tycel J. Phillips, MD, presents slides from the American Association for Cancer Research (AACR) Virtual Annual Meeting 2021 of results from the phase 3 CHRONOS-3 study of copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

Next Steps in Mantle Cell Lymphoma

March 2nd 2021